According to an AAD survey of HCPs, GI side effects are the #1 reason for noncompliance with oral antibiotics in teenagers*
*Based on 120 mg bioequivalence study
Study design: Open-label, randomized, single-dose, 2-period, 2-treatment, 2-sequence, crossover study under fasting conditions in adults (N=28) comparing DORYX MPC 120 mg to DORYX 100 mg.
Disclaimer: Not actual pill size
The usual dosage of DORYX MPC is 240 mg on the first day of treatment (administered 120 mg every 12 hours) followed by a maintenance dose of 120 mg daily.
The maintenance dose may be administered as a single dose or as 60 mg every 12 hours.
‡Restrictions and limitations apply. Please see Terms, Conditions, and Eligibility Criteria of Doryx® MPC Patient Savings Program.
INDICATION AND USAGE
Doryx® MPC (doxycycline hyclate delayed-release tablets) is a tetracycline-class antimicrobial indicated as adjunctive therapy for severe acne. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of Doryx® MPC and other antibacterial drugs, Doryx® MPC should be used only as indicated.
The usual dosage of Doryx® MPC is 240 mg on the first day of treatment (administered 120 mg every 12 hours) followed by a maintenance dose of 120 mg daily.
IMPORTANT SAFETY INFORMATION
Doxycycline is contraindicated in patients who have shown hypersensitivity to any of the tetracyclines. Tetracycline-class drugs, like Doryx® MPC (doxycycline hyclate delayed-release tablets), can cause fetal harm when administered to a pregnant woman. Doryx® MPC should be avoided if possible by nursing mothers, taking into account the importance of the drug to the mother. Doryx® MPC should not be used in children during tooth development (up to the age of 8 years). Concurrent use of tetracycline-class antibiotics with oral contraceptives may reduce their effectiveness.
Clostridium difficile associated diarrhea (CDAD) has been reported with nearly all antibacterial agents including doxycycline, and may range from mild diarrhea to fatal colitis.
Photosensitivity can occur with tetracycline-class drugs. Doryx® MPC patients should minimize or avoid excessive exposure to natural or artificial sunlight, and consider using sunscreen or sunblock. Advise patients to discontinue therapy at the first evidence of skin erythema.
Overgrowth of non-susceptible organisms, including fungi, may occur. Doryx® MPC should be discontinued if superinfection occurs and appropriate therapy instituted.
Intracranial Hypertension (IH) has been associated with the use of tetracyclines. Women of childbearing age who are overweight or have a history of IH are at greater risk for developing tetracycline-associated IH.
Adverse reactions observed in patients receiving tetracyclines include anorexia, nausea, vomiting, diarrhea, rash, photosensitivity, urticaria, and hemolytic anemia.
Please see full Prescribing Information here.
All registered trademarks are property of their respective owners